Blar i Bergen Open Research Archive på forfatter "Olsen, Inge Christoffer"

Viser treff 1-4 av 4

    • Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID‑19 (Bari‑SolidAct): a randomised, double‑blind, placebo‑controlled phase 3 trial 

      Trøseid, Marius; Arribas, José R.; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzic, Vida; Mazzaferri, Fulvia; Baño, Jesús Rodríguez; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, José-Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale Dawn; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel, Martin; Ader, Florence; Lacombe, Karine; Amdal, Cecilie Delphin; Rodrigues, Serge; Tonby, Kristian; Gaudet, Alexandre; Heggelund, Lars; Mootien, Joy; Johannessen, Asgeir; Møller, Jannicke Horjen; Pollan, Beatriz Diaz; Tveita, Anders Aune; Kildal, Anders Benjamin; Richard, Jean-Christophe; Dalgard, Olav; Simensen, Victoria Charlotte; Baldé, Aliou; de Gastines, Lucie; del Álamo, Marta; Aydin, Burç; Lund-Johansen, Fridtjof; Trabaud, Mary-Anne; Diallo, Alpha; Halvorsen, Bente; Røttingen, John-Arne; Tacconelli, Evelina; Yazdanpanah, Yazdan; Olsen, Inge Christoffer; Costagliola, Dominique; Study Group, EU-SolidAct (Journal article; Peer reviewed, 2023)
      Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct ...

    • Persistent pulmonary pathology after COVID‑19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase‑9 

      Lerum, Tøri Vigeland; Maltzahn, Niklas; Aukrust, Pål; Trøseid, Marius; Nezvalova-Henriksen, Katerina; Kåsine, Trine; Dyrhol-Riise, Anne Ma; Stiksrud, Birgitte; Haugli, Mette; Blomberg, Bjørn; Kittang, Bård Reiakvam; Johannessen, Asgeir; Hannula, Raisa; Aballi, Saad; Kildal, Anders Benjamin; Eiken, Ragnhild; Dahl, Tuva Børresdatter; Lund-Johansen, Fridtjof; Müller, Fredrik; Rivero, Jezabel Rodriguez; Meltzer, Carin; Einvik, Gunnar; Ueland, Thor; Olsen, Inge Christoffer; Barratt-Due, Andreas; Aaløkken, Trond Mogens; Skjønsberg, Ole Henning (Journal article; Peer reviewed, 2021)
      The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), ...

    • A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients 

      Jenum, Synne; Tonby, Kristian; Rueegg, Corina Silvia; Ruhwald, Morten; Kristiansen, Max Per; Bang, Peter; Olsen, Inge Christoffer; Sellæg, Kjersti; Røstad, Kjerstin; Mustafa, Tehmina; Tasken, Kjetil; Kvale, Dag; Mortensen, Rasmus; Riise, Anne Margarita Dyrhol (Journal article; Peer reviewed, 2021)
      Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) ...

    • Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: Study protocol for the randomised controlled phase II ReSScue trial 

      Hoffmann-Vold, Anna-Maria; Fretheim, Håvard Halland; Sarna, Vikas Kumar; Barua, Imon Shoumitra; Carstens, Maylen N.; Distler, Oliver; Khanna, Dinesh; Volkmann, Elizabeth R.; Midtvedt, Øyvind; Didriksen, Henriette; Dhainaut, Alvilde; Halse, Anne Kristine Hjorteseth; Bakland, Gunnstein; Pesonen, Maiju; Olsen, Inge Christoffer; Molberg, Øyvind (Journal article; Peer reviewed, 2021)
      Introduction: In the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is ...